Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary May 27, 2020 08:00 ET
Coverage Effective Immediately on One of the Largest Payor Networks in the U.S.
AMZEEQ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne
BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ® (minocycline) topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older, has been added to the prescription drug formulary of one of the largest payors in the U.S. AMZEEQ was approved by the U.S. Food and Drug Administration in October 2019.
“We are pleased with the continued expansion of our national coverage for AMZEEQ. With this additional plan under contract, we now have coverage for up to 60% of the total commercial lives in the United States,” said David Domzalski, Chief Executive Officer of Menlo. “This is great news as it allows for AMZEEQ to be more broadly accessible to millions of moderate to severe acne patients.”
Minocycline, a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, has not previously been available as a topical treatment due to its instability in traditional topical formulations. In AMZEEQ, Foamix has leveraged its proprietary Molecule Stabilizing Technology (MST™) platform to deliver minocycline in a foam-based vehicle that maintains the stability of the active ingredient while delivering it directly on the skin.
River of catalysts coming.
Ta Ta kids.
